First Tracks Biotherapeutics
TRAX · Nasdaq · United States
Share price · TRAX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TRAX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 20 Oct 2026+13.7%
- 9 Jul 2026+56.0%
Nothing announced by TRAX that day or the session before.
- 30 Jun 2026+18.3%
Nothing announced by TRAX that day or the session before.
Share of unusual movement by asset
For each asset, the share of TRAX's own-move activity since 21 Apr 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 3% |
| Sessions with no dated event | — | 97% |
No dated announcements about its assets since 21 Apr 2026.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | PD-1 (agonist)Monoclonal antibody | Rheumatoid Arthritis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $24M | $156M+ $0 short-term inv. | $31M-$17M operating cash flow | report ↗ |
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $26M | $168M+ $0 short-term inv. | $33M-$32M operating cash flow | report ↗ |
| 2026-Q1 | — | $34M | $248M+ $38M short-term inv. | $50M-$33M operating cash flow | report ↗ |
| 2025-Q3 | — | $33M | $110M | $42M-$31M operating cash flow | report ↗ |
| 2025-Q2 | — | $39M | $44M | $42M-$39M operating cash flow | report ↗ |
| 2025-Q1 | — | $41M | $99M | $47M-$45M operating cash flow | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $238M+ $73M short-term inv. | —-$143M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($66.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-01 | Lizzul Paul F. · Chief Medical Officer | Award / grant (derivative) | 42,500 | — | — | Form 4 |
| 2026-11-01 | STONE BENJAMIN · Chief Business Officer | Award / grant (derivative) | 42,500 | — | — | Form 4 |
| 2026-11-01 | Faga Daniel · director, President, CEO | Award / grant (derivative) | 136,000 | — | — | Form 4 |
| 2026-11-01 | Tamboli Ajim · Chief Financial Officer | Award / grant (derivative) | 42,500 | — | — | Form 4 |
| 2026-09-15 | Orwin John A · director | Option exercise | 1,300 | — | — | Form 4 |
| 2026-09-15 | Orwin John A · director | Option exercise (derivative) | 1,300 | — | — | Form 4 |
| 2026-09-02 | Ware J. Anthony · director | Option exercise | 39,265 | $5.74 | $225K | Form 4 |
| 2026-09-02 | Ware J. Anthony · director | Open-market sale | 39,265 | $44.78 | $1.8M | Form 4 |